Compare Enveric Biosciences Inc (ENVB) vs Hershey Co (HSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enveric Biosciences Inc vs Hershey Co — how do they compare? Enveric Biosciences Inc trades at $1.45 (market cap $6.20M), while Hershey Co trades at $181.98 (market cap $36.72B). The key difference: Hershey Co is far larger — about 5922.6× Enveric Biosciences Inc's market cap, and Hershey Co pays a 3.18% dividend while Enveric Biosciences Inc pays none. Which is the better fit depends on your goals.
| ENVB | HSY | |
|---|---|---|
Market Cap | $6.20M | $36.72B |
Sector | Health | Consumer Staples |
52-Week High | $17.40 | $236.28 |
52-Week Low | $1.27 | $162.31 |
Enterprise Value | $1.30M | $41.85B |
Dividend Yield | — | 3.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENVB trades at $1.55, down 0.64% with a bullish technical signal despite negative profitability. The company shows promising clinical progress with its lead candidate EB-003, supported by recent FDA guidance and positive preclinical data. While quarterly earnings consistently beat expectations, the company remains unprofitable with negative ROE and ROA. Analyst sentiment is positive with 75% buy ratings.
Investment outlook hinges on successful drug development milestones, with regulatory progress and intellectual property expansion providing catalysts. Key risks include clinical trial outcomes, cash burn from operations, and dependence on financing activities. The stock presents speculative growth potential for risk-tolerant investors focused on biotech innovation.
HSY trades at $182.35, down 0.37% on the day, with a bullish technical outlook supported by moving averages and a consensus price target of $196.78. Recent Q2 2026 earnings beat expectations with EPS of $1.90 versus $1.43, driven by margin recovery and pricing power. Revenue growth is steady, with 2025 revenue at $11.69B and net income margin at 12.24%, though profit margins have fluctuated year-over-year.
The stock offers upside potential from earnings momentum and dividend stability, with risks including competitive pressures and input cost volatility. Analyst sentiment is mixed, with 68.57% hold ratings, reflecting cautious optimism amid margin improvements and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →About Hershey Co
Hershey is a leading confectionery manufacturer in the U.S. (around a $25 billion market), controlling around 46% of the domestic chocolate space (per IRI). Beyond its namesake label, the firm's mix has expanded over the last 85 years and now consists of 100 brands, including Reese's, Kit Kat, Kisses, and Ice Breakers. Hershey's products are sold in about 80 countries, albeit with just a high-single-digit percentage of sales coming from markets outside the U.S., including Brazil, India, and Mexico. The firm has sought inorganic opportunities to extend its reach beyond its core confection business, adding Amplify Snack Brands and its Skinny Pop ready-to-eat popcorn to its mix and Pirate Brands (including the Pirate's Booty, Smart Puffs, and Original Tings brands) over the past few years.
Read more on HSY →
